Literature DB >> 68084

Antigenic studies of a VH fragment: demonstration of three sets of antigens, idiotypic, VH subgroup, and VH framework-specific antigens.

T E Michaelsen, O Forre, J B Natvig.   

Abstract

The antigenic properties of the VH region of immunoglobulin heavy chains were studied by means of a fragment corresponding to the variable part of the heavy chain of an IgG3 myeloma protein (KUP) and an antiserum made against this fragment. By hemagglutination, hemagglutination inhibition, and immunofluorescence techniques, it was shown that the anti-VH antiserum detected three sets of antigens in the VH region, namely idiotypic antigens, VH subgroup-specific antigens, and VH domain-(framework) specific antigens. The VH fragment inhibited in a VHII subgroup-specific hemagglutination inhibition test system. The VH fragment was thus antigenically similar to the tvh region found in the intact molecules and the light chains were not needed to express the VH subgroup antigens or the VH framework antigens.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 68084

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Demonstration of non-idiotypic variable heavy chain (VH) antigens on human peripheral blood lymphocytes.

Authors:  T Lea; T E Michaelsen; J B Natvig
Journal:  Immunology       Date:  1982-08       Impact factor: 7.397

2.  Anti-VH antibodies interfere with antigen binding by human T lymphocytes.

Authors:  T Lea; T E Michaelsen
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

3.  Sheep, rabbit and chicken antisera against a human VH fragment: reactivity with immunoglobulins and lymphocytes.

Authors:  T E Michaelsen; T Lea
Journal:  Immunology       Date:  1982-04       Impact factor: 7.397

4.  Immunoglobulin VH determinants defined by monoclonal antibodies.

Authors:  H Kubagawa; M Mayumi; J F Kearney; M D Cooper
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.